Screening for Preeclampsia
Welcome to this educational course on screening for preeclampsia in the first, second and third trimesters of pregnancy.
The course will cover:
- Background to PE, including definition, prevalence, implications, and pathogenesis
- Prevention of PE, by such measures as bed rest, dietary manipulations and use of low dose aspirin
- Prediction of PE by a combination of maternal characteristics and history and biochemical and biophysical markers
- Performance of screening for PE in the first, second and third trimesters of pregnancy
- Stratification of pregnancy management
Screening at 11-13 weeks identifies a high-risk group where administration of aspirin can substantially reduce the incidence of preterm preeclampsia.
Screening during the second and third trimesters identifies a high-risk group where intensive monitoring could lead to early diagnosis of preeclampsia and reduction in the adverse perinatal events associated with the disease.
The course lasts for about 1 hour, but it does not need to be completed in a single session.
Upon completing the course, you will obtain a certificate of attendance.
The course is mandatory as part of the FMF Certification in Screening for Preeclampsia.
Background to preeclampsia
Definition, prevalence, implications, pathogenesis
Prevention of preeclampsia
Bed rest and dietary manipulations
Low dose aspirin
Prediction of preeclampsia
Maternal characteristics and history
Biochemical markers: PLGF, sFLT-1, PAPP-A
Biophysical markers: MAP, UTPI
Performance of screening
Performance at 11-13 weeks
Performance at 20-24 weeks
Performance at 30-33 weeks
Performance at 35-37 weeks
Stratification of pregnancy management